Get to know our clinical trials
A 12-week exploratory study to evaluate the efficacy and safety and explore the mechanism of action of remibrutinib (LOU064) in adult patients with chronic urticaria
THE PURPOSE OF THE STUDY IS TO LEARN MORE ABOUT REMIBRUTINIB IN THE TREATMENT OF CHRONIC INDUCIBLE URTICARIA AND CHRONIC SPONTANEOUS URTICARIA IN ADULTS. IT WILL EVALUATE WHETHER IT IS SAFE, WELL TOLERATED AND EFFECTIVE AND ALSO EXPLORE HOW REMIBRUTINIB ACTS IN THE BODY AND ON THE SKIN.
Technical Summary
- RANDOMIZED, DOUBLE-BLIND (PARTICIPANT AND INVESTIGATOR), PLACEBO-CONTROLLED, 12-WEEK EXPLORATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY AND EXPLORE THE MECHANISM OF ACTION OF REMIBRUTINIB (LOU064) IN ADULT PATIENTS WITH CHRONIC URTICARIA.
- Code EudraCT: 2024-516355-41
- Protocol number: CLOU064M12101
- Promoter: Novartis
- Molecule/Drug: Remibrutinib (LOU064)
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.